Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript [Seeking Alpha]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Seeking Alpha
Company Participants Morgan Sanford - Vice President of Investor Relations Brian Goff - CEO & Director Sarah Gheuens - Chief Medical Officer and Head of Research & Development Tsveta Milanova - Chief Commercial Officer Cecilia Jones - Chief Financial Officer Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Gregory Renza - Truist Securities, Inc., Research Division Eric Schmidt - Cantor Fitzgerald & Co., Research Division Alec Stranahan - BofA Securities, Research Division Marc Frahm - TD Cowen, Research Division Emily Bodnar - H.C. Wainwright & Co, LLC, Research Division Jiayi Yuan - RBC Capital Markets, Research Division Presentation Operator Good day, and welcome to Agios Pharmaceuticals' Investor Conference Call and Webcast. [Operator Instructions] Please be advised that this call is being recorded at Agios' request. I would now like to turn the call over to Morgan Sanford, Head of Investor Relations at Agios. Mor
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios Pharmaceuticals (NASDAQ:AGIO) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Agios Pharmaceuticals (NASDAQ:AGIO) had its price target raised by analysts at Truist Financial Corporation from $32.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
- Here's Why Shares in Agios Pharmaceuticals Popped Today [Yahoo! Finance]Yahoo! Finance
- Agios Pharmaceuticals (NASDAQ:AGIO) had its price target raised by analysts at Bank of America Corporation from $32.00 to $34.00. They now have a "buy" rating on the stock.MarketBeat
- U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-ThalassemiaGlobeNewswire
AGIO
Earnings
- 10/30/25 - Beat
AGIO
Sec Filings
- 12/5/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form 4
- AGIO's page on the SEC website